Efficacy of methylprednisolone pulses in neuroendocrine cells hyperplasia of infancy: an early phase study (CORTICONEHI). - APHP230821

Assistance Publique Hopitaux De Paris0 个研究点目标入组 19 人开始时间: 2024年3月4日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Infant aged under 12 months, NEHI diagnosis based on: - The recently validated clinical Liptzin score =7/10 associated with a suggestive thoracic CT pattern with ground glass opacities confined to middle lobe, lingula, and paramediastinal lung areas OR - a clinical and thoracic CT suspicion and a lung biopsy showing an increased number of neuroendocrine cells in the epithelial airways area (at least one bronchiole with at least 10% of neuroendocrine cells), Oxygen requirement (awake and/or asleep) based on the usual pediatric recommendations, Followed in one of the RespiRare participating centers, Written informed consent of the holder(s) of its legal representative at the inclusion

•Other cause of chILD assessed by lab biology tests, genetic analysis for surfactant genes (if available), bronchoalveolar lavage, and/or lung biopsy, Patient treated with IV methylprednisolone pulses before (any time), Diabetes, Uncontrolled arterial hypertension, Absence of Health care insurance, Ongoing infection, Immunization with a live attenuated vaccine within the past two weeks, Long term treatment with Azithromycin and/or Hydroxychloroquine, Patients already included in an interventional study (RIPH1, clinical investigation or clinical trial)

发起方